Article Text

This article has a correction. Please see:

other Versions

PDF
EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI): Development of a consensus systemic disease activity index in primary Sjögren’s syndrome.
  1. Raphaèle Seror (raphaele.se{at}gmail.com)
  1. Bichat Hospital and Bicetre Hosptial, France
    1. Philippe Ravaud
    1. Bichat Hospital, France
      1. Simon Bowman
      1. University Hospital Birmingham, United Kingdom
        1. Gabriel Baron
        1. Bichat Hospital, France
          1. Athanasios Tzioufas
          1. University of Athens, Greece
            1. Elke Theander
            1. Malmö University Hospital, Lund University, Sweden
              1. Jacques-Eric Gottenberg
              1. Strasbourg University Hospital, France
                1. Hendrika Bootsma
                1. UMC Groningen, Netherlands
                  1. Xavier Mariette
                  1. Bicetre Hospital, France
                    1. Claudio Vitali
                    1. Hospital of Piombino, Italy

                      Abstract

                      Objective: To develop a disease activity index for patients with primary Sjögren’s syndrome (SS): the European League Against Rheumatism (EULAR) Sjögren’s Syndrome Disease Activity Index (ESSDAI).

                      Methods: Thirty-nine SS experts participated in an international collaboration, promoted by EULAR, to develop the ESSDAI. Experts identified 12 organ-specific “domains” contributing to disease activity. For each domain, features of disease activity were classified in 3 or 4 levels according to their severity. Data abstracted from 96 patients with systemic complications of primary SS were used to generate 702 realistic vignettes for which all possible systemic complications were represented. Using the 0-10 physician global assessment (PhGA) scale, each expert scored the disease activity of 5 patient profiles and 20 realistic vignettes. Multiple regression modelling, with PhGA used as the dependent variable, was used to estimate the weight of each domain.

                      Results: All 12 domains were significantly associated with disease activity in the multivariate model, domain weights ranged from 1 to 6. The ESSDAI scores varied from 2 to 47 and were significantly correlated with PhGA for both real patient profiles and realistic vignettes (r=0.61 and r=0.58, respectively, p<0.0001). Compared to 57 (59.4%) of the real patient profiles, 468 (66.7%) of the realistic vignettes were considered likely or very likely to be true.

                      Conclusion: The ESSDAI is a clinical index designed to measure disease activity in patients with primary SS. Once validated, such a standardized evaluation of primary SS should facilitate clinical research and should be helpful as an outcome measure in clinical trials.

                      Statistics from Altmetric.com

                      • Web Only Data ard.2009.110619

                        Files in this Data Supplement:

                      Request permissions

                      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                      Linked Articles

                      • Miscellaneous
                        BMJ Publishing Group Ltd and European League Against Rheumatism